Arnhold LLC Has $208,000 Position in Curis, Inc. (NASDAQ:CRIS)

Arnhold LLC reduced its position in shares of Curis, Inc. (NASDAQ:CRIS) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,348 shares of the biotechnology company’s stock after selling 1,302 shares during the period. Arnhold LLC owned approximately 0.28% of Curis worth $208,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their target price on Curis from $51.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, February 9th.

Curis Stock Performance

CRIS traded up $0.64 during midday trading on Tuesday, reaching $15.35. 7,313 shares of the company were exchanged, compared to its average volume of 34,165. The company’s fifty day moving average price is $12.30 and its 200 day moving average price is $10.60. The company has a market cap of $90.41 million, a price-to-earnings ratio of -1.71 and a beta of 3.72. Curis, Inc. has a one year low of $3.80 and a one year high of $19.60.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by ($0.12). Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The firm had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.95 million. During the same quarter in the previous year, the company posted ($2.40) EPS. As a group, sell-side analysts anticipate that Curis, Inc. will post -5.92 earnings per share for the current fiscal year.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.